Intercept Pharmaceuticals, Inc. Logo

Press releases

Date Title and Summary View
Toggle Summary Intercept to Announce Fourth Quarter and Full Year 2018 Financial Results on February 28, 2019
NEW YORK , Feb. 20, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its fourth quarter and full year 2018 financial
View HTML
Toggle Summary Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASH
First and largest successful pivotal Phase 3 study in patients with liver fibrosis due to NASH OCA achieves primary endpoint demonstrating statistically significant improvement in liver fibrosis without worsening of NASH at 18 months (p=0.0002) Intercept intends to file for regulatory approval in
View HTML
Toggle Summary Intercept Announces NASH and PBC Program Updates
Top-line data from the interim analysis of the Phase 3 REGENERATE trial of obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) patients with advanced fibrosis anticipated in Q1 2019 Phase 3 REVERSE trial of OCA in NASH patients with compensated cirrhosis projected to complete enrollment
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conference
NEW YORK , Jan. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept Announces New OCA Data to be Presented at The Liver MeetingĀ® 2018
NEW YORK , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple obeticholic acid (OCA)
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Business Update
Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019 Conference call scheduled for 8:30 a.m.
View HTML
Toggle Summary Intercept to Announce Third Quarter 2018 Financial Results on October 31, 2018
NEW YORK , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2018 financial results prior
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conference
NEW YORK , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept to Present at Upcoming Investor Conferences
NEW YORK , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the
View HTML
Toggle Summary Intercept Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019 Conference call scheduled for 8:30 a.m.
View HTML